Histoplasmosis: Recognition and treatment

Clinical Infectious Diseases

Volumn 19, Issue , 1994, Pages S19-S27

  Wheat, Joseph ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; INFECTION RISK; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AMPHOTERICIN B; FLUCONAZOLE; HISTOPLASMOSIS; HUMAN; ITRACONAZOLE; KETOCONAZOLE; SEROLOGIC TESTS;

EID: 0028018227     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/19.Supplement_1.S19     Document Type: Article

References (51)

1. Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia: WB Saunders, 1988.
2. Wheat LJ, Slama TG, Norton JA, et al. Risk factors for disseminated or fatal histoplasmosis. Ann Intern Med 1982;96:159-63.
3. Wheat LJ. Wass J, Norton J. Kohler RB, French MLV. Cavitary histoplasmosis occurring during two large urban outbreaks: analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine (Baltimore) 1984;63:201-9.
4. Wheat LJ. Diagnosis and management of histoplasmosis. Eur J Clin Microbiol Infect Dis 1989:8:480-90.
5. Wheat LJ. Systemic fungal infections: diagnosis and treatment. I. Histoplasmosis. Infect Dis Clin North Am 1988;2:841-59.
6. Rubin H, Furcolow ML, Yates JL, BrasherCA. The course and prognosis of histoplasmosis. Am J Med 1959;27:278-88.
7. Wheat LJ, Slama TG, Eitzen HE, Kohler RB, French MLV, Bieseckler JL. A large urban outbreak of histoplasmosis: clinical features. Ann Intern Med 1981;94:331-7.
8. Sathapatayavongs B, Batteiger BE, Wheat LJ, Slama TG, Wass JL. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983;62:263-70.
9. Kataria YP, Campbell PB, Burlingham BT. Acute pulmonary histoplasmosis presenting as adult respiratory distress syndrome: effect of therapy on clinical and laboratory features. South Med J 1981;74:534-7.
10. Greenwood MF, Holland P. Tracheal obstruction secondary to Histo-plasma mediastinal granuloma. Chest 1972;62:642-5.
11. Rabinowitz JG, Prater W, Silver J, Phillips JC, Wieder S. Mediastinal histoplasmosis. Mt Sinai J Med 1980;47:356-63.
12. Loyd JE, Tillman BF, Atkinson JB, des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Mcdicine (Baltimore) 1988;67:295-310.
13. Coss KC, Wheat LJ, Conces DJ Jr, Brashear RE, Hull MT. Esophageal fistula complicating mediastinal histoplasmosis: response to amphotericin B. Am J Med 1987;83:343-6.
14. Alcorn GL. Clinical problems in cardiopulmonary disease: histoplasmosis with symptomatic lymphadenopathy. Clinical evaluation by R. A. Goodwin, M. D. Chest 1980;77:213-5.
15. Dines DE, Payne WS, Bernatz PE, Pairolero PC. Mediastinal granuloma and fibrosing mediastinitis. Chest 1979;75:320-4.
16. Gilliland MD. Scott LD, Walker WE. Esophageal obstruction caused by mediastinal histoplasmosis: beneficial results of operation. Surgery 1984;95:59-62.
17. Woods LP. Mediastinal Histoplasma granuloma causing tracheal compression in a 4-year-old child. Surgery 1965;58:448-52.
18. Garrett HE Jr, Roper CL. Surgical intervention in histoplasmosis. Ann Thorac Surg 1986;42:711-22.
19. Wheat LJ, Stein L, Corya BC, et al. Pericarditis as a manifestation of histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983;62:110-9.
20. Rosenthal J, Brandt KD, Wheat LJ, Slama TG. Rheumatologic manifestations of histoplasmosis in the recent Indianapolis epidemic. Arthr Rheum 1983;26:1065-70.
21. Goodwin RA Jr, Snell JD, Hubbard WW, Terry RT. Early chronic pulmonary histoplasmosis. Am Rev Respir Dis 1966;93:47-61.
22. Furcolow ML. Course and prognosis of untreated histoplasmosis. JAMA 1961;177:292-6.
23. Goodwin RA Jr, Shapiro JL, Thurman GH, Thurman SS, des Prez RM. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine (Baltimore) 1980;59:1-33.
24. Morris RJ, Betts RF, Douglas RG Jr, Jacox RF. Recurrent disseminated histoplasmosis. South Med J 1978;71:621-3.
25. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990;69:361-74.
26. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986;314:83-8.
27. Goodwin RA, Nickell JA, des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 1972;51:227-46.
28. Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg 1992;54:1053-8.
29. Gallis HA, Drew RH. Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
30. Huang Y, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 1986;30:206-10.
31. Connolly PA, Durkin MM, Wheat LJ. Evaluation of the activity of three antifungal agents against the yeast form of patient isolates of Histoplasma capsulation as determined by macrobroth in vitro susceptibility testing [abstract no 749], In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993.
32. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:610-6.
33. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
34. Furcolow ML. Comparison of treated and untreated severe histoplasmosis. JAMA 1963;183:121-7.
35. Dismukes WE, Cloud G, Bowles C, et al. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985;103:861-72.
36. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992;93:489-97.
37. Wheat LJ, Hafner RE, Ritchie M, Schneider D. Itraconazole (Itra) is effective treatment for histoplasmosis in AIDS; prospective multicenter non-comparative trial [abstract no 1206], In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1992.
38. Norris S, McKinsey D, Lancaster D, Wheat J. Retrospective evaluation of fluconazole maintenance therapy for disseminated histoplasmosis in AIDS. Am J Med 1994 (in press).
39. McKinsey DS, Gupta MR, Driks MR, Smith DL, O’Connor M. Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy [letter]. Am J Med 1992;92:225-7.
40. Slama TG. Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole. Am J Med 1983;74:70-3.
41. Sarosi GA, Johnson PC. Disseminated histoplasmosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14(suppl l):S60-7.
42. Blum RA, D’Andrea DT. Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114:755-7.
43. Stein AG, Daneshmend TK, Warnock DW, Bhaskar N, Burke J, Hawkey CJ. The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol 1989;27:105P-6P.
44. Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schen-tag JJ. Effects of ranitidine and sulcralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991;35:1765-71
45. Tucker RM. Denning DW, Hanson LH. et al. Interaction ofazoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
46. Negroni R, Robles AM, Arechavala A, Taborda A. Itraconazole in human histoplasmosis. Mycoses 1988;32:123-30.
47. Viviani MA, Tortorano AM, Langer M, et al. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 1989;18:151-65.
48. Tucker RM. Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6.
49. Wheat LJ, Connolly-Stringfield P, Blair R, et al. Effect of successful treatment with amphotericin B on Histoplasma capsulatum variety capsulatum polysaccharide antigen levels in patients with AIDS and histoplasmosis. Am J Med 1992:92:153-60.
50. Wheat LJ, Connolly-Stringfield P, Blair R, Connolly K., Garringer T, Katz BP. Histoplasmosis relapse in patients with AIDS: detection using Histopiasma capsulatum variety capsulatum antigen levels. Ann Intern Med 1991:115:936-41.
51. Buckley HR. Richardson MD, Evans EG, Wheat LJ. Immunodiagnosis of invasive fungal infection. J Med Vet Mycol 1992;30(suppl 1):249—60.